Global Health Share Price Falls 2.79% After Q1 Results
Global Health falls 2.79% to Rs 1,376.90. Q1 FY27 PAT Rs 158.7 crore vs Rs 159 crore (-0.2% YoY). Revenue Rs 1,304 crore vs Rs 1,031 crore approx (+26.5% YoY).
Updated: 31 Jul 2026 • 12:24 pm
Posted by:
The Global Health share price fall after Q1 results theme was in focus on Friday, with Global Health shares moving 2.79% to Rs 1,376.90, from a previous close of Rs 1,416.40, after the company reported its results for the quarter ended June 2026.
Global Health reported a profit after tax of Rs 158.7 crore for Q1 FY27, against Rs 159 crore in the year-ago quarter, a change of -0.2%. Revenue for the quarter stood at Rs 1,304 crore, compared with Rs 1,031 crore approx a year earlier, a change of +26.5%.
Click Here – Get Free Investment Predictions
Global Health Q1 FY27 Results: Key Numbers
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Profit After Tax | Rs 158.7 crore | Rs 159 crore | -0.2% |
| Revenue | Rs 1,304 crore | Rs 1,031 crore approx | +26.5% |
Why Global Health Shares Moved 2.79% Today
Check the Univest Screener for sector-linked stocks
Revenue grew strongly on higher patient volumes, though profit stayed nearly flat as the network continues to expand and absorb new-hospital costs.
About Global Health
Operator of Medanta hospitals, a multi-specialty healthcare chain with tertiary and quaternary care centres.
Download the Univest iOS App or Univest Android App to track Global Health's stock price and quarterly results.
What to Watch Going Forward
Investors tracking Global Health should watch management commentary on demand trends, cost pressures and full-year guidance in the coming quarters, since forward-looking statements often matter as much as the headline quarterly numbers for how the stock trades over the following weeks.
Conclusion
The Global Health share price fall after Q1 results move reflects the market's reaction to the company's latest quarterly performance. Investors should evaluate the stock against its own growth trajectory and valuation, and consult a SEBI-registered financial advisor before making any investment decision.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Investors continuing to track the Global Health share price fall after Q1 results story should watch how the stock trades in the sessions ahead.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Global health share price fall after q1 results
Why did Global Health share price fall after Q1 results?
Ans. Global Health shares moved 2.79% after the company reported Q1 FY27 profit after tax of Rs 158.7 crore, a change of -0.2% from Rs 159 crore a year earlier, on revenue of Rs 1,304 crore.
What was Global Health's profit in Q1 FY27?
Ans. Global Health reported a profit after tax of Rs 158.7 crore for the quarter ended June 2026, compared with Rs 159 crore in the same quarter a year earlier.
What was Global Health's revenue in Q1 FY27?
Ans. Global Health's revenue for Q1 FY27 stood at Rs 1,304 crore, compared with Rs 1,031 crore approx a year earlier, a change of +26.5%.
What is Global Health's current share price?
Ans. Global Health shares were trading at Rs 1,376.90 today, falling 2.79% from the previous close of Rs 1,416.40.
Should I buy Global Health shares after the Q1 results move?
Ans. Investment decisions should be based on individual research and risk appetite; consult a SEBI-registered financial advisor before buying or selling shares after any results-driven move.
Where can I track Global Health's live share price?
Ans. Global Health's live share price and quarterly result updates can be tracked on the Univest platform alongside SEBI-registered research.
Recent Articles
IREDA Share Price Jumps About 7% as IREDA Shares Log a Seventh Straight Gain Despite a 20% Fall in One Year: What the Volume Surge and Q2 Numbers Show
9 November 2026
Taparia Tools Share Price Hits 5% Upper Circuit Before the Record Date: What the Rs 40 Taparia Tools Dividend, Q2 Profit and a Tiny Free Float Mean
9 November 2026
SPARC Share Price Surges Up to 11% on 9 November 2026: Why Sun Pharma Advanced Research Shares Rose Despite Weak Sentiment on D-Street and What to Check
9 November 2026
IRB Infra Share Price Surges 6% After IRB Infra Q2 Results: Is a Bigger Breakout on the Cards, and What the Profit Jump Does and Does Not Tell Investors
9 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
IREDA Share Price Jumps About 7% as IREDA Shares Log a Seventh Straight Gain Despite a 20% Fall in One Year: What the Volume Surge and Q2 Numbers Show
Taparia Tools Share Price Hits 5% Upper Circuit Before the Record Date: What the Rs 40 Taparia Tools Dividend, Q2 Profit and a Tiny Free Float Mean
SPARC Share Price Surges Up to 11% on 9 November 2026: Why Sun Pharma Advanced Research Shares Rose Despite Weak Sentiment on D-Street and What to Check
IRB Infra Share Price Surges 6% After IRB Infra Q2 Results: Is a Bigger Breakout on the Cards, and What the Profit Jump Does and Does Not Tell Investors
MIC Electronics Share Price Rises 3% Despite a Weak Market on 9 November 2026: What This Small-Cap Stock Under Rs 50 Offers and the Risks to Check
Popular this week
HFCL Share Price in a 5% HFCL Lower Circuit on 9 November 2026, Down 21% in a Month: What Is Known After Record Q2 FY27 Profit and What Lies Ahead
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times